{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003096","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.726656+00:00","generated_at":"2026-06-15T11:26:58.305096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anika Q1 revenue up 3% to $37.9M but net loss widens to $10.4M","bullets":["OA Pain Mgmt rev $22.6M (+8% YoY); Joint Preservation & Restoration rev $13.5M (+11% YoY).","Net loss ($10.4M) or ($0.71)/share; adjusted net loss ($5.3M) or ($0.36)/share.","Adj EBITDA ($1.2M) vs +$2.6M in Q1 2022; gross margin 60% (adj 64%).","FY 2023 rev guidance reaffirmed at $158-163M; $20M share buyback authorized.","Post-quarter: settled Parcus arbitration, cooperation with Caligan, added director Fischetti."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003096","json":"https://secwatch.observer/filing/0001171843-23-003096.json","markdown":"https://secwatch.observer/filing/0001171843-23-003096.md","text":"https://secwatch.observer/filing/0001171843-23-003096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/f8k_050923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:26:58.305096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79a433ea7583d8303eb1df8f5c0498ab0df7fd6d","claim":"Anika Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $37.9 million, net income ($10.4) million, EPS ($0.71) per share.","evidence_excerpt":"First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter of 2022. Osteoarthritis (OA) Pain Management 1 revenue of $22.6 million, up 8% Joint Preservation and Restoration revenue of $13.5 million, up 11% Non-Orthopedic 1 revenue of $1.8 million, down 49% Gross margin was 60%, including $1.6 million of non-cash acquisition-related expenses; Adjusted gross margin 2 was 64%. Net loss was ($10.4) million, or ($0.71) per share, which includes the Parcus Medical unitholder arbitration settlement, as well as shareholder activism and other non-recurring corporate costs, compared to net loss of ($2.9) million, or ($0.20) per share, in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$37.9 million"},{"label":"Net income","value":"($10.4) million"},{"label":"EPS","value":"($0.71) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f12eb2d576659de6011f1559ff2029476e4b0175","claim":"Anika Therapeutics, Inc. reported fiscal year 2023 results: revenue between $158 million and $163 million. Guidance reaffirmed.","evidence_excerpt":"Fiscal 2023 Revenue Outlook The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues*.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323003096/0001171843-23-003096-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"between $158 million and $163 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}